NCT06505369 - Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

October 31, 2028

Conditions

Multiple Myeloma

Interventions

DRUG

Daratumumab

Daratumumab will be administered by SC injection

DRUG

Bortezomib

Bortezomib will be administered by SC injection

DRUG

Lenalidomide

Lenalidomide will be administered by oral route

DRUG

Dexamethasone

Dexamethasone will be administered by oral route

DRUG

Talquetamab

Talquetamab will be administered by SC injection

DRUG

Teclistamab

Teclistamab will be administered by SC injection

Trial Locations (7)

2100

NOT_YET_RECRUITING

Copenhagen University Hospital (Rigshospitalet), Copenhagen

4068

NOT_YET_RECRUITING

Stavanger University Hospital, Stavanger

5000

NOT_YET_RECRUITING

Odense University Hospital, Odense

7030

NOT_YET_RECRUITING

St. Olavs Hospital, Trondheim

7100

NOT_YET_RECRUITING

Vejle hospital, Vejle

13419

RECRUITING

North Estonia Medical Centre, Tallinn

0450

NOT_YET_RECRUITING

Oslo University Hospital, Oslo Myeloma Centre, Oslo